“Going forward, patients and medical teams have a choice of two pathways for chest pain relief: chest pain medication or PCI," one cardiologist said. 

Browse through some of the many highlights from TCT 2023 in San Francisco.

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

The system, designed for patients with uncontrolled hypertension who are unresponsive to medication, uses ultrasound ablation to target nerves in the renal arteries, increasing blood flow. This approval comes just months after an FDA advisory panel voted in favor of the system. 

Medical facilities and distributors have been advised to immediately discontinue the use of these devices due to a significant labeling issue. 

IVUS was especially effective when treating patients with a complex coronary anatomy, researchers found. 

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.